As filed with the Securities and Exchange Commission on March 23, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
SOLENO THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
| | |
Delaware | | 77-0523891 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification Number) |
203 Redwood Shores Pkwy, Suite 500
Redwood City, CA 94065
(Address of principal executive offices, including zip code)
Amended and Restated 2014 Equity Incentive Plan
2020 Inducement Equity Incentive Plan
(Full title of the plan)
Anish Bhatnagar
Chief Executive Officer
Soleno Therapeutics, Inc.
203 Redwood Shores Pkwy, Suite 500
Redwood City, CA 94065
(Name and address of agent for service)
(650) 213-8444
(Telephone number, including area code, of agent for service)
Copies to:
Elton Satusky
Jesse Schumaker
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304
(650) 493-9300
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one)
| | | | | | |
Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐